Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis.
about
Rational Design of Fatty Acid Amide Hydrolase Inhibitors That Act by Covalently Bonding to Two Active Site ResiduesInhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future AntidepressantsPharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategiesBiochemical and mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase inhibitionLigand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.Assessment of a spectrophotometric assay for monoacylglycerol lipase activity.2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspectiveEnhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modalityMicrowave Assisted Synthesis of Sodium Sulfonates Precursors of Sulfonyl Chlorides and Fluorides.Sulfonyl fluoride inhibitors of fatty acid amide hydrolase.Discovery of potent and reversible monoacylglycerol lipase inhibitors.Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effectsRefined homology model of monoacylglycerol lipase: toward a selective inhibitor.Endocannabinoid enzyme engineering: soluble human thio-monoacylglycerol lipase (sol-S-hMGL).Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathologySpecific Inter-residue Interactions as Determinants of Human Monoacylglycerol Lipase Catalytic Competency: A ROLE FOR GLOBAL CONFORMATIONAL CHANGES.Highly predictive ligand-based pharmacophore and homology models of ABHD6.Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire.Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism.Mass spectrometry-based GPCR proteomics: comprehensive characterization of the human cannabinoid 1 receptor.A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activityA critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors.Active-site inhibitors modulate the dynamic properties of human monoacylglycerol lipase: a hydrogen exchange mass spectrometry studyLipolytic proteomics.Monoglyceride lipase: Structure and inhibitors.A comparison of novel, selective fatty acid amide hydrolase (FAAH), monoacyglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models.Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors.Effects of Distal Mutations on the Structure, Dynamics and Catalysis of Human Monoacylglycerol Lipase.
P2860
Q27677344-D380ADCD-3343-4625-8656-413758BA3E3FQ28082891-FAA48403-3877-4EDF-9199-F8A53007C181Q28241318-70476FF1-BC80-4052-BB36-0AB5A36F30FFQ28483214-19499035-DC7B-4322-931C-75733D834ABEQ30373403-81075A6C-8DF1-4B1E-A5CC-167559A59B05Q30406301-36951286-3341-4196-A4AA-D5903B8D29C3Q33733994-6D7148C6-B549-4243-BDB3-280125D072C1Q33749499-853663F2-30EF-43CD-B859-98A58BB60947Q33781776-6C79348C-53E0-44C5-A646-5D700048C3E8Q34018061-E6F1B14A-E869-40EA-AAB1-BF6206176B82Q34363783-12131F2C-03AB-46AA-80CA-5FF40A69451CQ34452685-236F9C1C-D4FA-4C76-915F-280F14989FB3Q34556411-C8EE0497-D2E9-4786-9D59-DF5259BD03FDQ34946680-1C852632-DDFE-4D7D-8AB7-DE4E14547F8AQ35841379-91E0E422-CA5C-4AF2-9091-BFB556127893Q36104505-1C305287-0AC7-4649-A4EF-E1F578D4FE1BQ36345411-4F866326-65F2-4997-852E-3F3FA57A3448Q36548313-17363438-A607-4C98-B1B8-C4D35411D0E4Q36612107-099B0C7A-7929-4E9F-BAB7-EA5470FA8570Q36720905-2FCBAC81-5BA0-41DA-8230-996155BFED95Q36949890-D2FC3552-6F9E-4EA4-81D1-89464662187FQ36971343-77479DB4-1529-4345-966D-F0BFBD7E06F5Q36971376-C2306807-6298-477B-9040-9CDDE58D67B9Q37016733-061AE4D2-1549-4ACB-AF58-BCEE242F4A39Q37332639-334889A9-601E-4A11-8E94-A84C0FE7A54FQ37374110-AA4B0420-374F-4A6D-A98B-2E76C5F4B2E2Q37990875-670BD618-10D8-45CE-A54A-F9C40B3BE7D4Q38555486-088E8E6A-594C-4136-83BF-C14E4E0255DDQ41155213-ED7503C3-1B03-408F-8A6C-DF408B634573Q47763157-BE58DD93-6527-463F-98A5-9D99E11F77EAQ48147518-AD2C1326-0C97-4468-B702-C7E060F38557
P2860
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Covalent inhibitors of human m ...... metry and mutational analysis.
@en
Covalent inhibitors of human m ...... metry and mutational analysis.
@nl
type
label
Covalent inhibitors of human m ...... metry and mutational analysis.
@en
Covalent inhibitors of human m ...... metry and mutational analysis.
@nl
prefLabel
Covalent inhibitors of human m ...... metry and mutational analysis.
@en
Covalent inhibitors of human m ...... metry and mutational analysis.
@nl
P2093
P2860
P1476
Covalent inhibitors of human m ...... metry and mutational analysis.
@en
P2093
David R Janero
Ioannis Karageorgos
John Williams
Lakshmipathi Pandarinathan
Meghan Johnston
Srinivasan C Krishnan
P2860
P304
P356
10.1016/J.CHEMBIOL.2008.06.008
P577
2008-08-01T00:00:00Z